Literature DB >> 24801198

Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study.

Nobuhiro Takiguchi1, Masazumi Takahashi, Masami Ikeda, Satoshi Inagawa, Shugo Ueda, Takayuki Nobuoka, Manabu Ota, Yoshiaki Iwasaki, Nobuyuki Uchida, Yasuhiro Kodera, Koji Nakada.   

Abstract

BACKGROUND: Although proximal gastrectomy (PG) is widely accepted as a function-preserving operation for early upper-third gastric cancer, postoperative disorders, such as reflux or gastric stasis, have often been pointed out. From the perspective of postoperative disorder, the choice of total gastrectomy (TG) or PG for such cancers is still controversial. By using the newly developed Postgastrectomy Syndrome Assessment Scale (PGSAS)-45, the quality of life after TG and PG was compared.
METHODS: The PGSAS-45 consists of 45 items composed of the SF-8 and GSRS scales and 22 new items. The main outcomes are measured by seven subscales (SS) covering symptoms, physical and mental component summary (SF-8), meals (amount and quality), ability to work, dissatisfaction for daily life, and change in body weight. A total of 2,368 eligible questionnaires were acquired from 52 institutions. From these, 393 patients with TG and 193 patients with PG were selected and compared.
RESULTS: The PG was better than TG in terms of body weight loss (TG 13.8% vs. PG 10.9%; p = 0.003), necessity for additional meals (2.4 vs. 2.0; p < 0.001), diarrhea SS (2.3 vs. 2.0; p = 0.048), and dumping SS (2.3 vs. 2.0; p = 0.043). There were no differences in the other main outcome measures.
CONCLUSIONS: Proximal gastrectomy appears to be valuable as a function-preserving procedure for early upper-third gastric cancer.

Entities:  

Mesh:

Year:  2014        PMID: 24801198     DOI: 10.1007/s10120-014-0377-8

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  38 in total

1.  Outcomes of mass screening for gastric carcinoma.

Authors:  Chikara Kunisaki; Junko Ishino; Susumu Nakajima; Hisahiko Motohashi; Hirotoshi Akiyama; Masato Nomura; Goro Matsuda; Yuichi Otsuka; Hidetaka Andrew Ono; Hiroshi Shimada
Journal:  Ann Surg Oncol       Date:  2006-01-17       Impact factor: 5.344

2.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

3.  Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands.

Authors:  A E Dassen; V E P P Lemmens; L V van de Poll-Franse; G J Creemers; S J Brenninkmeijer; D J Lips; A A M Vd Wurff; K Bosscha; J W W Coebergh
Journal:  Eur J Cancer       Date:  2010-03-08       Impact factor: 9.162

Review 4.  Function-preserving surgery for gastric cancer.

Authors:  Hitoshi Katai
Journal:  Int J Clin Oncol       Date:  2006-10       Impact factor: 3.402

Review 5.  Quality of life in gastric cancer.

Authors:  Ad-A Kaptein; Satoshi Morita; Junichi Sakamoto
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

6.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

7.  Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site.

Authors:  Hongyu Wu; Jennifer A Rusiecki; Kangmin Zhu; John Potter; Susan S Devesa
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-16       Impact factor: 4.254

8.  Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach.

Authors:  Pernilla Lagergren; Peter Fayers; Thierry Conroy; Hubert J Stein; Orhan Sezer; Richard Hardwick; Eva Hammerlid; Andrew Bottomley; Eric Van Cutsem; Jane M Blazeby
Journal:  Eur J Cancer       Date:  2007-08-15       Impact factor: 9.162

9.  Trends in incidence of oesophageal and stomach cancer subtypes in Europe.

Authors:  Jessie Steevens; Anita A M Botterweck; Miranda J M Dirx; Piet A van den Brandt; Leo J Schouten
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-06       Impact factor: 2.566

10.  Effects of reconstruction methods on a patient's quality of life after a proximal gastrectomy: subjective symptoms evaluation using questionnaire survey.

Authors:  Masanori Tokunaga; Naoki Hiki; Shigekazu Ohyama; Souya Nunobe; Akira Miki; Tetsu Fukunaga; Yasuyuki Seto; Takeshi Sano; Toshiharu Yamaguchi
Journal:  Langenbecks Arch Surg       Date:  2008-12-10       Impact factor: 3.445

View more
  61 in total

1.  Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: randomized controlled trial CCG1101.

Authors:  Yuichi Ito; Takaki Yoshikawa; Michitaka Fujiwara; Hiroshi Kojima; Takanori Matsui; Yoshinari Mochizuki; Haruhiko Cho; Toru Aoyama; Seiji Ito; Kazunari Misawa; Hiroshi Nakayama; Yuki Morioka; Akiharu Ishiyama; Chie Tanaka; Satoshi Morita; Junichi Sakamoto; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2015-08-14       Impact factor: 7.370

Review 2.  Quality of life: A critical outcome for all surgical treatments of gastric cancer.

Authors:  Michael D McCall; Peter J Graham; Oliver F Bathe
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Can Proximal Gastrectomy with Double-Tract Reconstruction Replace Total Gastrectomy? A Propensity Score Matching Analysis.

Authors:  Hyo Jung Ko; Ki Hyun Kim; Si-Hak Lee; Cheol Woong Choi; Su Jin Kim; Chang In Choi; Dae-Hwan Kim; Dong-Heon Kim; Sun-Hwi Hwang
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

Review 4.  Laparoscopic sentinel node navigation surgery for early gastric cancer.

Authors:  Shinichi Kinami; Takeo Kosaka
Journal:  Transl Gastroenterol Hepatol       Date:  2017-05-09

5.  Laparoscopic esophagogastrostomy using a knifeless linear stapler after proximal gastrectomy.

Authors:  Masaki Ohi; Yuji Toiyama; Takahito Kitajima; Tsunehiko Shigemori; Hiromi Yasuda; Yoshinaga Okugawa; Hiroyuki Fujikawa; Yoshiki Okita; Takeshi Yokoe; Junichiro Hiro; Toshimitsu Araki; Masato Kusunoki
Journal:  Surg Today       Date:  2019-06-20       Impact factor: 2.549

6.  Laparoscopic proximal gastrectomy with oblique jejunogastrostomy.

Authors:  Kimitaka Tanaka; Yuma Ebihara; Yo Kurashima; Yoshitsugu Nakanishi; Toshimichi Asano; Takehiro Noji; Soichi Murakami; Toru Nakamura; Takahiro Tsuchikawa; Keisuke Okamura; Toshiaki Shichinohe; Satoshi Hirano
Journal:  Langenbecks Arch Surg       Date:  2017-05-10       Impact factor: 3.445

7.  Effect of early oral feeding on length of hospital stay following gastrectomy for gastric cancer: a Japanese multicenter, randomized controlled trial.

Authors:  Nobuyuki Shimizu; Eiji Oki; Yutaka Tanizawa; Yutaka Suzuki; Susumu Aikou; Chikara Kunisaki; Takashi Tsuchiya; Ryoji Fukushima; Yuichiro Doki; Shoji Natsugoe; Yasunori Nishida; Masaru Morita; Naoki Hirabayashi; Fumihiko Hatao; Ikuo Takahashi; Yasuhiro Choda; Yoshiaki Iwasaki; Yasuyuki Seto
Journal:  Surg Today       Date:  2018-05-02       Impact factor: 2.549

8.  Prophylactic Total Gastrectomy: a Prospective Cohort Study of Long-Term Impact on Quality of Life.

Authors:  Jennifer Muir; Melyssa Aronson; Mary-Jane Esplen; Aaron Pollett; Carol J Swallow
Journal:  J Gastrointest Surg       Date:  2016-10-17       Impact factor: 3.452

Review 9.  Function-preserving gastrectomy for gastric cancer in Japan.

Authors:  Eiji Nomura; Kunio Okajima
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

10.  Functional Advantages of Proximal Gastrectomy with Jejunal Interposition Over Total Gastrectomy with Roux-en-Y Esophagojejunostomy for Early Gastric Cancer.

Authors:  Masaki Ohashi; Shinji Morita; Takeo Fukagawa; Ichiro Oda; Ryoji Kushima; Hitoshi Katai
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.